Gallium 68 PSMA-11: all 63 studies that test it

Page 1 of 1. Open to participants first (11), then studies with results posted, then the rest; newest registration first within each.

• 68Ga-PSMA-11 PET/MRI for Selecting Men With Prostate Cancer for Focal TherapyNot yet recruitingNCT07747493Not applicable
• Response With Interim PSMA PET in Metastatic Castration-sensitive Prostate Cancer for Optimization of Adaptive Metastasis-directed Radiotherapy DeliveryNot yet recruitingNCT07674771Early Phase 1
• 68Ga-PSMA-11 PET Imaging for Diagnosing Prostate Cancer, a Head-to-head Comparison With mpMRIRecruitingNCT07209878Phase 2/3
• Preoperative Planning With PSMA-PET in Melanoma Surgery TrialRecruitingNCT06560905Phase 2
• PET/MRI to Stage Prostate Cancer PatientsRecruitingNCT06484361Phase 2
• An Investigational Scan (Ga-68 PSMA-11 PET/CT) for Detection of Disease Recurrence or Progression in Patients With GliomaRecruitingNCT06444412Phase 2
• 68Ga-AAZTA-093 PET/CT: First-in-human StudyRecruitingNCT06437496Early Phase 1
• PSMA PET Response Guided SabR in High Risk PcaRecruitingNCT06044857Phase 1
• 68Ga-PSMA-11 Efficacy in Detecting BCR Prostate Cancer in Chinese PatientsRecruitingNCT05847348Phase 3
• 68Ga-P16-093 and 68Ga-PSMA-11 PET/CT Imaging in the Same Group of Primary Prostate Cancer PatientsRecruitingNCT05324332Not applicable
• 68Ga-PSMA-11 PET/CT in Patients With Various Types of CancerRecruitingNCT04831541Early Phase 1
• 68Ga-PSMA-11 PET/CT Screening Prior to 177Lu-PSMA-617 Therapy for Patients With Metastatic Castrate Resistant Prostate CancerCompletedNCT05547386Phase 3Results posted
• 68Ga PSMA PET Imaging for the Treatment of Advanced Liver CancerCompletedNCT05176223Phase 2Results posted
• 68Ga-PSMA-Dual-Contrast PET/MRI or PET/CT for Early Detection of Liver CancerCompletedNCT04762888Phase 2Results posted
• 68Ga-PSMA-11 PET for the Diagnosis of Metastatic Castration Resistant Prostate CancerTerminatedNCT04716725Phase 2Results posted
• 68 Ga-PSMA for High Risk Prostate CancerCompletedNCT04614363Phase 1/2Results posted
• HDR Brachytherapy 68-Ga-RM2 PET, 68-Ga-PSMA-11 PET &Multi Parametric MRI in Prostate CancerTerminatedNCT04264208Phase 2Results posted
• The Role of 68Gallium PSMA-11 in Enhancing Diagnosis of Primary and Metastatic Prostate CancerCompletedNCT04179968Phase 2Results posted
• PSMA-PET/MRI Unfavorable-Risk Target Volume Pilot StudyTerminatedNCT04176497Phase 2Results posted
• 68-Ga PSMA 11 PET/MRI and 68-Ga RM2 PET/MRI for Evaluation of Prostate Cancer Response to HIFU TherapyCompletedNCT03949517Phase 1/2Results posted
• 68Ga PSMA 11 PET/MRI and 68Ga RM2 PET/MRI for Biopsy Guidance in Patients With Suspected Prostate CancerCompletedNCT03809078Phase 2Results posted
• Gallium-68 PSMA-11 PET Imaging in Prostate Cancer PatientsCompletedNCT03803475Phase 3Results posted
• Radiolabeled Gallium-68 (68Ga-PSMA) for PET/CT Imaging to Detect Prostate CancerTerminatedNCT03689582Phase 2Results posted
• PSMA Imaging of Localized Prostate CancerCompletedNCT03675451Phase 2Results posted
• Gallium-68 Prostate Specific Membrane Antigen PET in Diagnosing Patients With Thyroid CancerTerminatedNCT03463889Phase 2Results posted
• Gallium-68 PSMA-11 PET in Patients With Biochemical RecurrenceCompletedNCT03396874Phase 2Results posted
• Gallium-68 PSMA-11 Positron Emission Tomography (PET) Imaging in Patients With Biochemical RecurrenceCompletedNCT03353740Phase 3Results posted
• Gallium-68 PSMA-11 PET in Intermediate to High-risk Preprostatectomy PatientsCompletedNCT02919111Phase 2/3Results posted
• Gallium-68 PSMA-11 PET in Patients With Biochemical RecurrenceCompletedNCT02918357Phase 2/3Results posted
• 68Ga-PSMA-11 PET/MRI in Finding Tumors in Patients With Intermediate or High-Risk Prostate Cancer Undergoing SurgeryCompletedNCT02678351Phase 2/3Results posted
• 68Ga-PSMA PET/CT in Detecting Prostate Cancer Recurrence in Patients With Elevated PSA After Initial TreatmentCompletedNCT02673151Phase 2/3Results posted
• Evaluation of Gallium-68-HBED-CC-PSMA Imaging in Prostate Cancer PatientsCompletedNCT02611882Phase 2Results posted
• 68Ga-PSMA PET/CT or PET/MRI in Evaluating Patients With Recurrent Prostate CancerCompletedNCT02488070Phase 1/2Results posted
• PSMA PET Combined With MRI for the Detection of PCaActive, not recruitingNCT07052214Phase 3
• Study to Assess [177Lu]Lu-PSMA-R2 (AAA602) and [225Ac]Ac-PSMA-R2 (AAA802) in Participants With PSMA-positive HRLPCWithdrawnNCT06881823Phase 1/2
• An Investigational Scan (Ga-68 PSMA-11 PET/CT) for the Detection of Therapy Response in Patients With Metastatic Adenoid Cystic CarcinomaCompletedNCT06521775Phase 2
• Clinical Applications of Integrated PET/MR and PET/CT in the Diagnosis and Treatment of Prostate Cancer.SuspendedNCT06355843Not applicable
• Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal FunctionActive, not recruitingNCT06004661Phase 2
• PET/MR for Prostate Cancer Restaging: a Phase II Prospective Monocentric StudyCompletedNCT05806853Phase 2
• Ga-68-PSMA-11 in Men With Prostate CancerTerminatedNCT05744115Phase 3
• 68Ga-P15-041 and 68Ga-PSMA-11 PET/CT Imaging in the Same Group of Prostate Bone MetastasisStatus unknownNCT05627778Phase 1/2
• Diagnosis of Renal Cell Carcinoma on 68Ga-PSMA PET-CT and Radioligand Therapy With 177Lu-EB-PSMA-617Status unknownNCT05170555Not applicable
• Gallium-68 PSMA-11 PET in Participants With Prostate CancerWithdrawnNCT05034562Phase 2
• Clinical Application of 68Ga-PSMA PET/MR for Diagnosis and Staging in Hepatocellular CarcinomaStatus unknownNCT05006326Not applicable
• Pharmacokinetics of IA and IV Ga68-PSMA-11 InfusionCompletedNCT04976257Early Phase 1
• Diagnosis of Adenoid Cystic Carcinoma on 68Ga-PSMA-617 PET-CT and Therapy With 177Lu-EB-PSMA-617Status unknownNCT04801264Early Phase 1
• An Investigational Scan (68Ga-PSMA-11 PET) for the Imaging of Prostate CancerActive, not recruitingNCT04777071Phase 2
• 68Ga PSMA-11 PET/CT in Recurrent Prostate CancerWithdrawnNCT04483414Phase 2
• PSMA PET/MRI or PSMA PET/CT for Evaluation of Liver CancerCompletedNCT04310540Early Phase 1
• Impact of Monosodium Glutamate on 68GA-PSMA-11, PET Imaging Biodistribution in Patients With Prostate CancerCompletedNCT04282824Early Phase 1
• Effect of Androgen Receptor Signaling Inhibitors on 68Ga-PSMA-11 PET/CT Imaging in Patients With Castration-Resistant Prostate CancerTerminatedNCT04279561Phase 1
• PSMA-PET/MRI Low- and Intermediate-Risk Prostate CancerWithdrawnNCT04243941Phase 2
• 68Ga-PSMA-11 PET for the Diagnosis of Biochemically Recurrent Prostate CancerCompletedNCT04216134Phase 1
• 68GA-PSMA-11 PET/CT Scan in Impacting Treatment Strategies for Patients With Prostate CancerCompletedNCT04050215Phase 2
• PSMA and C-11 Choline PET in Patients With Biochemical Recurrence of Prostate CancerCompletedNCT03768349Early Phase 1
• Gallium Ga 68-labeled PSMA-11 PET/CT and Fluciclovine F18 PET/CT in Imaging Participants With Recurrent Prostate Cancer After SurgeryCompletedNCT03515577Phase 2
• Investigation of PSMA PET/CT as an Imaging Biomarker in Solid TumorsCompletedNCT03453528Not applicable
• Ga-68-PSMA-11 in High-risk Prostate CancerCompletedNCT03362359Phase 1/2
• 68Ga-PSMA PET/CT in Prostate CancerCompletedNCT03001869Phase 3
• Biodistribution/Reproducibility Ga-68 PSMA-HBED-CCCompletedNCT02952469Early Phase 1
• 68Ga-PSMA HBED-PET/CT in the Evaluation of the Biochemical Relapse in Patients With a History of Prostate Cancer Radically TreatedCompletedNCT02920229Not applicable
• PET/MRI in Patients With Suspected Prostate CancerCompletedNCT02659527Phase 3
• 68Ga-PSMA PET-CT Scan for Diagnosis and Management of Prostate CancerStatus unknownNCT02282137Phase 2

← Gallium 68 PSMA-11 overview